PMID- 32438272
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210702
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Print)
IS  - 0169-5002 (Linking)
VI  - 145
DP  - 2020 Jul
TI  - SC-002 in patients with relapsed or refractory small cell lung cancer and large 
      cell neuroendocrine carcinoma: Phase 1 study.
PG  - 126-131
LID - S0169-5002(20)30387-1 [pii]
LID - 10.1016/j.lungcan.2020.04.017 [doi]
AB  - OBJECTIVES: This phase 1 study investigated safety/tolerability, 
      pharmacokinetics, and preliminary efficacy of SC-002, a delta-like ligand 
      3-directed antibody-drug conjugate, in advanced small cell lung cancer and large 
      cell neuroendocrine carcinoma. MATERIALS AND METHODS: Eligible patients received 
      SC-002 at 1 of 7 dose levels during the dose-escalation portion of the study. 
      RESULTS: Thirty-five enrolled patients received >/=1 dose of SC-002. Twenty-three 
      (66%) patients experienced serious adverse events (AEs), 37% considered related 
      to SC-002. Grade 3/4 AEs occurred in 21 (60%) and 2 (6%) patients; the most 
      common were effusion and hypoalbuminemia. One grade 5 AE occurred in 1 patient. 
      Five (14%) patients achieved a partial response and no patients achieved a 
      complete response. CONCLUSION: SC-002 treatment was associated with systemic 
      toxicity and limited efficacy.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Morgensztern, Daniel
AU  - Morgensztern D
AD  - Washington University School of Medicine, St. Louis, MO, USA. Electronic address: 
      danielmorgensztern@wustl.edu.
FAU - Johnson, Melissa
AU  - Johnson M
AD  - Sarah Cannon Research Institute, Nashville, TN, USA.
FAU - Rudin, Charles M
AU  - Rudin CM
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Rossi, Michael
AU  - Rossi M
AD  - AbbVie Inc., South San Francisco, CA, USA.
FAU - Lazarov, Mirella
AU  - Lazarov M
AD  - AbbVie Inc., South San Francisco, CA, USA.
FAU - Brickman, Daniel
AU  - Brickman D
AD  - AbbVie Inc., South San Francisco, CA, USA.
FAU - Fong, Abraham
AU  - Fong A
AD  - AbbVie Inc., South San Francisco, CA, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02500914
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200512
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Cephalosporins)
RN  - P256HB60FF (SC002)
SB  - IM
MH  - *Carcinoma, Large Cell/drug therapy
MH  - *Carcinoma, Neuroendocrine/drug therapy
MH  - Cephalosporins
MH  - Humans
MH  - *Lung Neoplasms/drug therapy
MH  - *Small Cell Lung Carcinoma/drug therapy
PMC - PMC8173700
MID - NIHMS1704936
OTO - NOTNLM
OT  - Antibody-drug conjugate
OT  - Delta-like ligand 3
OT  - Large cell neuroendocrine carcinoma
OT  - Pyrrolobenzodiazepine
OT  - SC-002
OT  - Small cell lung cancer
COIS- Declaration of Competing Interest Daniel Morgensztern: Consultant fees: AbbVie, 
      Bristol-Myers Squibb, PharmaMar, Boehringer Ingelheim, Takeda, Gilead. Melissa 
      Johnson: Research funding to institution: AbbVie, Acerta, Adaptimmune, Apexigen, 
      Array BioPharma, AstraZeneca, Atreca, BeiGene, Birdie, Boehringer Ingelheim, 
      Checkpoint Therapeutics, Corvus Pharmaceuticals, CytomX, Daiichi Sankyo, Dynavax, 
      Lilly, EMD Serono, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, 
      Gritstone Oncology, Guardant Health, Hengrui Therapeutics, Immunocore, Incyte, 
      Janssen, Jounce Therapeutics, Kadmon Pharmaceuticals, Loxo Oncology, Lycera, 
      Merck, Mirati Therapeutics, Neovia Oncology, Novartis, OncoMed Pharmaceuticals, 
      Pfizer, Regeneron Pharmaceuticals, Sanofi, Shattuck Labs, Stemcentrx, Syndax 
      Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, University of Michigan, 
      WindMIL, TCR2 Therapeutics, Arcus Biosciences, Ribon Therapeutics, Amgen; 
      consulting/advisory role (spouse): contract lobbyist for Astellas, contract 
      lobbyist for Otsuka Pharmaceuticals; consulting/advisory role (self) - all to 
      institution: AbbVie, Achilles Therapeutics, AstraZeneca, Atreca, Boehringer 
      Ingelheim, Calithera Biosciences, Genentech, GlaxoSmithKline, Gritstone Oncology, 
      Guardant Health, Incyte, Janssen, Lilly, Loxo Oncology, Merck, Mirati 
      Therapeutics, Novartis, Pfizer, Ribon Therapeutics, Sanofi, Association of 
      Community Cancer Centers; food/beverage/travel expenses: AbbVie, Astellas, 
      AstraZeneca, Boehringer Ingelheim, Clovis, Daiichi Sankyo, EMD Serono, 
      Bristol-Myers Squibb, Exelixis, Genentech/Roche, Incyte, Merck, Pfizer, Sysmex 
      Inostics, Vapotherm, Janssen, Lilly, Novartis, Sanofi. Charles M. Rudin: 
      Consultant for: AbbVie, Amgen, Ascentage, AstraZeneca, Celgene, Daiichi Sankyo, 
      Genentech/Roche, Ipsen, Loxo, PharmaMar, and Vivotek. Scientific advisory boards 
      of Bridge Medicines and Harpoon Therapeutics. Michael Rossi, Mirella Lazarov, 
      Daniel Brickman, Abraham Fong: AbbVie employees and may own stock.
EDAT- 2020/05/22 06:00
MHDA- 2021/06/22 06:00
PMCR- 2021/07/01
CRDT- 2020/05/22 06:00
PHST- 2020/03/16 00:00 [received]
PHST- 2020/04/13 00:00 [revised]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
PHST- 2021/07/01 00:00 [pmc-release]
AID - S0169-5002(20)30387-1 [pii]
AID - 10.1016/j.lungcan.2020.04.017 [doi]
PST - ppublish
SO  - Lung Cancer. 2020 Jul;145:126-131. doi: 10.1016/j.lungcan.2020.04.017. Epub 2020 
      May 12.